Advertisement

Clinical development of the GnRH agonist leuprolide acetate depot

Open AccessPublished:November 21, 2022DOI:https://doi.org/10.1016/j.xfre.2022.11.011
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Leuprolide acetate is the first GnRH agonist that entered clinical development following the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the USA and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection.